Tvastar Genkalp Raises $1.3M Series A to Revolutionize Liver Cancer Detection with Episcreen™ Liver

Tvastar Genkalp is excited to announce a significant funding milestone that reinforces its commitment to revolutionizing early cancer detection and patient care.

The company recently raised $1,300,000 in a strategic funding round designed to accelerate the development and dissemination of its groundbreaking diagnostic technologies.

Established in May 2021 as a leader in molecular diagnostics, Tvastar Genkalp has quickly become synonymous with innovative liquid biopsy solutions, particularly in the realm of blood-based cancer diagnostics.

At the heart of its cutting-edge portfolio is Episcreen™ Liver, a screening test specifically designed for the early detection of Hepatocellular carcinoma (HCC).

Rigorously validated through a comprehensive study involving over 750 patients, Episcreen™ Liver has demonstrated a sensitivity rate of 90%—dramatically outperforming the traditional AFP biomarker, which records only a 50% sensitivity rate.

Furthermore, the test has proven its substantial clinical value by correctly identifying 92% of HCC cases that were missed by AFP, offering a potentially life-saving advantage for patients worldwide.

The newly secured funds will be strategically deployed to expand Tvastar Genkalp’s research and development efforts, enhance clinical trials, and broaden access to its state-of-the-art diagnostic solutions.

By investing in advanced analytics and further refining the liquid biopsy technology, Tvastar Genkalp aims to solidify its position at the forefront of molecular diagnostics and ultimately improve outcomes for patients facing liver cancer.

This funding round not only underscores investor confidence in the company’s innovative approach but also marks a pivotal step forward in the mission to transform cancer diagnostics and save lives.